Introduction: Multidrug-resistant tuberculosis (MDR-TB) is a life-threatening condition needing long poly-chemotherapy regimens. As no systematic reviews/meta-analysis is available to comprehensively evaluate the role of delamanid (DLM), we evaluated its effectiveness and safety. Methods: We reviewed the relevant scientific literature published up to January 20, 2022. The pooled success treatment rate with 95% confidence intervals (CI) was assessed using a random-effect model. We assessed studies for quality and bias, and considered P<0.05 to be statistically significant. Results: After reviewing 626 records, we identified 25 studies that met the inclusion criteria, 22 observational and 3 experimental, with 1276 and 411 patients, respectively. In observational studies the overall pooled treatment success rate of DLM-containing regimens was 80.9% (95% CI 72.6-87.2) with no evidence of publication bias (Begg's test; P >0.05). The overall pooled treatment success rate in DLM and bedaquiline-containing regimens was 75.2% (95% CI 68.1-81.1) with no evidence of publication bias (Begg's test; P >0.05). In experimental studies the pooled treatment success rate of DLM-containing regimens was 72.5 (95% CI 44.2-89.8, P <0.001, I2: 95.1%) with no evidence of publication bias (Begg's test; P >0.05). Conclusions: In MDR-TB patients receiving DLM, culture conversion and treatment success rates were high despite extensive resistance with limited adverse events.

Delamanid-containing regimens and multidrug-resistant tuberculosis: A systematic review and meta-analysis / Nasiri, Mohammad Javad; Zangiabadian, Moein; Arabpour, Erfan; Amini, Sirus; Khalili, Farima; Centis, Rosella; D'Ambrosio, Lia; Denholm, Justin T; Schaaf, H Simon; van den Boom, Martin; Kurhasani, Xhevat; Dalcolmo, Margareth Pretti; Al-Abri, Seif; Chakaya, Jeremiah; Alffenaar, Jan-Willem; Akkerman, Onno; Silva, Denise Rossato; Torrico, Marcela Muňoz; Seaworth, Barbara; Pontali, Emanuele; Saderi, Laura; Tiberi, Simon; Zumla, Alimuddin; Migliori, Giovanni Battista; Sotgiu, Giovanni. - In: INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. - ISSN 1201-9712. - (2022). [10.1016/j.ijid.2022.02.043]

Delamanid-containing regimens and multidrug-resistant tuberculosis: A systematic review and meta-analysis

Saderi, Laura;Sotgiu, Giovanni
2022-01-01

Abstract

Introduction: Multidrug-resistant tuberculosis (MDR-TB) is a life-threatening condition needing long poly-chemotherapy regimens. As no systematic reviews/meta-analysis is available to comprehensively evaluate the role of delamanid (DLM), we evaluated its effectiveness and safety. Methods: We reviewed the relevant scientific literature published up to January 20, 2022. The pooled success treatment rate with 95% confidence intervals (CI) was assessed using a random-effect model. We assessed studies for quality and bias, and considered P<0.05 to be statistically significant. Results: After reviewing 626 records, we identified 25 studies that met the inclusion criteria, 22 observational and 3 experimental, with 1276 and 411 patients, respectively. In observational studies the overall pooled treatment success rate of DLM-containing regimens was 80.9% (95% CI 72.6-87.2) with no evidence of publication bias (Begg's test; P >0.05). The overall pooled treatment success rate in DLM and bedaquiline-containing regimens was 75.2% (95% CI 68.1-81.1) with no evidence of publication bias (Begg's test; P >0.05). In experimental studies the pooled treatment success rate of DLM-containing regimens was 72.5 (95% CI 44.2-89.8, P <0.001, I2: 95.1%) with no evidence of publication bias (Begg's test; P >0.05). Conclusions: In MDR-TB patients receiving DLM, culture conversion and treatment success rates were high despite extensive resistance with limited adverse events.
2022
Delamanid-containing regimens and multidrug-resistant tuberculosis: A systematic review and meta-analysis / Nasiri, Mohammad Javad; Zangiabadian, Moein; Arabpour, Erfan; Amini, Sirus; Khalili, Farima; Centis, Rosella; D'Ambrosio, Lia; Denholm, Justin T; Schaaf, H Simon; van den Boom, Martin; Kurhasani, Xhevat; Dalcolmo, Margareth Pretti; Al-Abri, Seif; Chakaya, Jeremiah; Alffenaar, Jan-Willem; Akkerman, Onno; Silva, Denise Rossato; Torrico, Marcela Muňoz; Seaworth, Barbara; Pontali, Emanuele; Saderi, Laura; Tiberi, Simon; Zumla, Alimuddin; Migliori, Giovanni Battista; Sotgiu, Giovanni. - In: INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. - ISSN 1201-9712. - (2022). [10.1016/j.ijid.2022.02.043]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11388/256503
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 22
  • ???jsp.display-item.citation.isi??? ND
social impact